Background
==========

Osteoporosis is a widely prevalent, age-related skeletal disorder characterized by compromised bone strength and an increased risk of bone fracture \[[@B1],[@B2]\]. Osteoporotic fractures, particularly hip (femoral neck) fractures that usually require hospitalisation and surgery, are frequently associated with poor outcomes including the need for institutional care and death \[[@B1],[@B3]\]. Simple interventions that can prevent or delay the onset of osteoporosis and its complications are needed to stem the projected increase in the burden of osteoporosis due to the increasing age and other demographic changes in the population \[[@B4],[@B5]\].

An increased plasma concentration of total homocysteine (tHcy) has been postulated as a novel, potentially treatable risk factor for osteoporotic fractures, including hip fractures \[[@B2],[@B6]-[@B8]\]. In one prospective population-based study, the highest quartile of tHcy was associated with a two-fold increase in risk of fracture (risk ratio \[RR\] 1.9, 95% confidence interval \[CI\] 1.4-2.6), and the association was continuous; with each standard deviation (SD) increase in tHcy, the risk of fracture increased by 30% (RR 1.3, 95% CI 1.1-1.5) \[[@B9]\]. These findings have been validated in other populations \[[@B10],[@B11]\]. Further, the strength of the association between high tHcy and fracture risk (RR 1.9 for every SD increase) is of similar magnitude to that attributable to other accepted risk factors for hip fracture such as age over 75 years (RR 2.3), falls in the previous year (1.9), low bone density (1.6) and current smoking (1.6) \[[@B9]\]. Several biological mechanisms have been postulated to account for this association but it is still uncertain whether the association is causal, confounded or biased due to reverse causality \[[@B2],[@B6],[@B12]-[@B14]\]. As raised tHcy can be lowered with B-vitamin therapy, \[[@B15],[@B16]\] it is possible to determine whether tHcy is a causal risk factor for bone fracture by means of randomised controlled trials (RCTs) of B-vitamins vs. placebo. Four RCTs have examined the effect of B-vitamins on biomarkers of bone turnover but have been limited by the use of surrogate outcomes for fracture risk, lack of statistical power due to the inclusion of small numbers of subjects and/or use of healthy volunteers \[[@B17]-[@B20]\]. Two RCTs of B-vitamins on bone fracture risk have produced conflicting results. The largest, involving 5522 patients, failed to show any significant impact of B-vitamins on fracture incidence despite a 3.3 μmol/L lower tHcy and a mean follow-up of five years \[[@B21],[@B22]\]. The only positive intervention study to date was undertaken in 628 elderly Japanese patients with significant residual hemiplegia at least one year following stroke \[[@B23]\]. Those treated with combination folate and vitamin B12 had a 75% reduction (adjusted RR 0.24, 95% CI 0.11-0.53) in the incidence of fracture at two years. However, the study population was highly selected and characterized by severe disability, very high homocysteine concentrations (mean 19.9 μmol/L), and an unusually high fracture rate in the control group, approximately 10 times the rate found in the average Japanese population of the same age \[[@B24]\].

In light of the uncertainty surrounding the role of tHcy in the pathogenesis of osteoporosis and bone fracture, we prospectively examined the occurrence of any osteoporotic fracture and osteoporotic hip fractures in the VITAmins TO Prevent Stroke (VITATOPS) trial of patients with recently symptomatic cerebrovascular disease treated with either B-vitamins or placebo.

Methods
=======

The rationale, methods, CONSORT flowchart and primary results of the VITATOPS trial have been published \[[@B25],[@B26]\]. In summary, VITATOPS was an investigator-led, prospective, randomised, double-blind, placebo-controlled trial in which 8164 patients with recent (within seven months) stroke or transient ischemic attack (TIA) were recruited between November 19 1998 and December 31 2008, and randomly assigned to receive either one tablet daily of B-vitamins (folic acid 2 mg, vitamin B~6~ 25 mg, vitamin B~12~ 500 μg) or matching placebo. Final follow-up was 30 June 2009 ensuring a minimum six months and up to 10.5 years on study medication.

The study was conducted in accordance with principles of good clinical practice and the Declaration of Helsinki, and received ethics approval in the United Kingdom from the Multicentre Research Ethics Committee for Scotland A, in New Zealand from the Multi-region Ethics Committee and from local research ethics committees applicable to each participating centre. A full list of the 127 participating centres is available in an additional file \[see Additional file [1](#S1){ref-type="supplementary-material"}\]. All patients provided written informed consent before enrolment.

Demographic and clinical characteristics of the participants recorded at baseline included; age, sex, ethnicity (of participants and their parents and grandparents), clinical details of the qualifying cerebrovascular event, current medications, past medical history (major vascular events, revascularisation procedures, depression), vascular risk factors (hypertension, smoking, hypercholesterolaemia, diabetes mellitus, ischaemic heart disease, atrial fibrillation, peripheral artery disease), alcohol intake, Oxford Handicap Score, Hospital Anxiety and Depression Score, and Mini Mental State Examination score. Cox's proportional hazards models were used to adjust for differences in baseline variables.

Investigators were encouraged but not obligated to take blood samples from study participants who consented to these optional tests, to measure blood concentrations of tHcy, red cell folate and vitamin B12 at study entry and/or at the time of their final follow-up visit. Fasting plasma tHcy was measured by high-performance liquid chromatography, on venous blood samples collected after an overnight fast.

The primary outcome measure for the main VITATOPS study was the composite of any stroke, myocardial infarction or death due to vascular causes. In this substudy the main outcome measure was occurrence of any clinically apparent osteoporotic fracture. Osteoporotic hip fractures and time till first fracture were secondary outcome measures. Non-osteoporotic fractures were excluded from analysis.

Patients were reviewed six-monthly and data on clinical fracture outcomes were based on information obtained from clinical history, radiology reports, hospital discharge reports and health records. All hospitalisations including those for fracture were recorded prospectively, and from 2004 (following publication of the potential association between homocysteine and fracture risk \[[@B6]\]) until the end of the trial in June 2009 all clinically apparent fractures whether hospitalised or not, were recorded prospectively.

A masked adjudication committee audited all fractures. Fractures were classified as osteoporotic if they were reported to be osteoporotic by the investigator; and involved the hip (neck of femur), wrist (distal radius) or spine (vertebral), or occurred spontaneously or in the context of minor trauma; and if there was no other apparent cause (e.g. severe trauma, metastatic cancer).

The primary statistical analysis for this substudy was an intention-to-treat analysis of the incidence of any osteoporotic fracture in the placebo and B-vitamin treatment groups over the duration of follow-up. This was added to the pre-established analysis plan in 2004. A secondary per protocol on-treatment analysis would exclude any patients found to be invalid after randomisation or who had cross-over in treatment during follow-up.

The event rates were calculated as the number of events that occurred during the follow-up period divided by the total number of patients randomised. The risk ratios (treatment/placebo) of the fracture rates in the treatment and placebo groups and their 95% confidence intervals were calculated to describe the treatment effect. We used Kaplan-Meier methods to construct cumulative time-to-event curves for the two groups and the main comparison was based on a log-rank test.

We did stepwise logistic multivariable regression analysis to determine the independent risk factors for osteoporotic fracture in the study population.

Two sided significance tests were used throughout and a two-sided p-value \< 0.05 was considered significant.

Results
=======

Full details of baseline demographic data, clinical characteristics, laboratory results, adherence to therapy, follow up rates and primary (non-fracture) outcome data have previously been published \[[@B26]\]. Participants had a mean age of 62.6 years (SD 12.5 years) and 64% were male, 42% of Western European descent and 75% had an Oxford Handicap Scale of two or less indicating either no lifestyle restrictions or ability to manage without assistance.

At randomisation, 4089 participants were allocated to B-vitamins and 4075 to placebo. A total of 579 participants (7.1% B-vitamins, 6.8% placebo, p = 0.39) were taking medications for prevention or treatment of osteoporosis. These were predominantly calcium supplements - alone (n = 462) or in combination with other medications (n = 41). The remainder were vitamin D (n = 24), bisphosphonates (n = 24), hormone replacement therapy (n = 18) or a combination of these (n = 10).

Follow-up
---------

Follow-up continued for a median duration of 3.4 years per person (Inter Quartile Range \[IQR\] 2.0-5.5 years, range 0--9 years) with mean adherence to study treatment of 2.8 years (IQR 1.2-4.7 years). The longer duration of follow-up (0.6 years) reflects those patients who discontinued trial drugs but agreed to continue with follow-up.

A total of 425 patients (5.2%) withdrew from study follow-up prior to the inclusion of fractures as a specified reportable outcome event in 2004.

Osteoporotic fracture incidence
-------------------------------

At the end of the trial, any clinically apparent osteoporotic fracture occurred in 67 (1.64%) participants assigned B-vitamins and 78 (1.91%) assigned to placebo (RR 0.86, 95% CI 0.62-1.18); and hip fractures occurred in 34 (0.83%) assigned B-vitamins and 36 (0.88%) assigned to placebo (RR 0.94, 95% CI 0.59-1.5) (Table  [1](#T1){ref-type="table"}). There was no significant impact of treatment on any other osteoporotic fracture subtype. A subgroup analysis excluding the 425 (5.2%) patients who left the study prior to the 2004 inclusion of all fractures as a specified reportable outcome event, rather than just hospitalised fractures, did not alter the findings. Compared with placebo, treatment with B-vitamins was not associated with any significant difference in the time to first fracture for any osteoporotic fracture or hip fractures (Figures  [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). A secondary per protocol on-treatment analysis also showed no impact of treatment on any osteoporotic fracture outcome after removal of patients found to be invalid after randomisation or who had cross-over in treatment during follow-up; either placebo group patients taking B-vitamins or B-vitamin group patients stopping their treatment (p = 0.85).
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###### 

Osteoporotic fracture outcomes according to treatment group

  **Osteoporotic fractures**   **B-Vitamins**   **Placebo**   **Relative risk**   **p-value**
  ---------------------------- ---------------- ------------- ------------------- -------------
  Any                          67 (1.6)         78 (1.1)      0.86 (0.62,1.18)    0.32
  Hip                          34 (0.8)         36 (0.9)      0.94 (0.59,1.50)    0.77
  Wrist                        7 (0.2)          8 (0.1)       0.87 (0.32,2.40)    0.78
  Thoracic spine               4 (0.1)          5 (0.1)       0.80 (0.21,2.97)    0.70
  Other                        26 (0.6)         35 (0.9)      0.74 (0.45,1.23)    0.24

Note: Only first fracture was used for each type of events. One patient could have multiple different types of fractures, so sum of fracture types could be more than the total of fractures.

Predictors of osteoporotic fracture
-----------------------------------

On multivariate analysis independent predictors of any osteoporotic fracture were female sex (adjusted odds ratio \[OR\] 2.58, 95% CI 1.80-3.70), age \> 64 years (OR 4.18, 95% CI 2.60-6.72), Western European ethnicity (OR 3.86, 95% CI 2.52-5.92) and use of anti-osteoporosis medication at randomization (OR 1.78, 95% CI 1.11-2.86). (Tables  [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). In participants who volunteered to have their homocysteine levels measured at baseline (n = 1205), there was no difference between those with (n = 40; mean tHcy 14.2 ±6.22 μmol/L) or without subsequent fracture (n = 1165; mean tHcy 14.3 ±8.56 μmol/L, p = 0.43). Homocysteine levels at follow-up were not associated with fracture outcomes in either treatment group (Table  [4](#T4){ref-type="table"}).

###### 

Baseline characteristics for patients with and without any osteoporotic fracture

  **Baseline characteristic**                           **With any fracture**   **Without fracture**   **p-value**
  ---------------------------------- ------------------ ----------------------- ---------------------- -------------
  Sex                                Male               55 (37.9)               5163 (64.4)            \<.001
                                     Female             90 (62.1)               2854 (35.6              
  Age                                \<65 yrs           23 (15.9)               4276 (53.3)            \<.001
                                     \> = 65 yrs        122 (84.1)              3743 (46.7)             
  Ethnicity                          Western European   105 (78.9)              3171 (42.3)            \<.001
                                     Oriental           15 (11.3)               1898 (24.7)             
                                     South Asian        7 (5.3)                 2046 (26.6)             
                                     Other              6 (4.5)                 566 (7.4)               
  Oxford Handicap Score              \> = 3             35 (24.7)               1859 (23.8)            0.18
                                     \<3                107 (75.4)              5952 (76.2)             
  Smoking (ever)                     Yes                72 (49.7)               3947 (49.9)            0.43
                                     No                 73 (50.3)               3966 (50.1)             
  Alcohol (any)                      Yes                54 (37.2)               2269 (28.3)            0.20
                                     No                 91 (62.8)               5748 (71.7)             
  Diabetes                           Yes                24 (16.6)               1875 (23.7)            0.21
                                     No                 121 (83.5)              6047 (76.3)             
  Stroke                             Yes                28 (19.3)               1254 (15.8)            0.28
                                     No                 117 (80.7)              6664 (84.2)             
  Myocardial infarction              Yes                15 (10.3)               583 (7.4)              0.33
                                     No                 130 (89.7)              7317 (92.6)             
  Hypertension                       Yes                105 (72.4)              5632 (71.1)            0.45
                                     No                 40 (27.6)               2285 (28.9)             
  Depression                         Yes                16 (16.0)               528 (7.4)              0.003
                                     No                 84 (84.0)               6650 (92.6)             
  Antidepressant medication          Yes                24 (16.6)               536 (6.8)              \<.001
                                     No                 121 (83.5)              7332 (93.2)             
  Corticosteroid medication          Yes                3 (2.1)                 47 (0.6)               0.011
                                     No                 142 (97.9)              7972 (99.4)             
  Any Osteoporosis Medication \*     Yes                23 (15.9)               556 (6.9)              \<.001
                                     No                 122 (84.1)              7463 (93.1)             
  Homocysteine level at baseline †                      (n = 40)                (n = 1165)             0.43
  mean (SD)                          14.2 (6.2)         14.3 (8.6)                                     

\* Including Calcium, Vitamin D, Bisphosphonates and Hormone replacement therapy;

† Not all participants had homocysteine levels measured at Baseline.

###### 

Any osteoporotic fracture outcomes according to baseline characteristics and treatment group

  **Baseline characteristic**                      **B-Vitamins**   **Placebo**   **p-value**   **P-value for interaction**
  ----------------------------- ------------------ ---------------- ------------- ------------- -----------------------------
  Sex                           Male               27 (1.0)         28 (1.1)      0.90          0.50
                                Female             40 (2.7)         50 (3.4)      0.21           
  Age                           \<65 yrs           12 (0.6)         11 (0.5)      0.90          0.57
                                \> = 65 yrs        55 (2.8)         67 (3.5)      0.28           
  Ethnicity                     Western European   48 (2.9)         57(3.5)       0.35          0.65
                                Oriental           9 (0.9)          6 (0.6)       0.42           
                                South Asian        4 (0.4)          3 (0.3)       0.74           
                                Other              1 (0.4)          5 (1.7)       0.12           
  Oxford Handicap Score         \> = 3             14 (1.5)         21 (2.2)      0.18          0.34
                                \<3                51 (1.7)         56 (1.9)      0.63           
  Smoking (ever)                Yes                36 (1.8)         36 (1.8)      0.96          0.30
                                No                 31 (1.5)         42 (2.1)      0.16           
  Alcohol (any)                 Yes                26 (2.2)         28 (2.5)      0.71          0.76
                                No                 41 (1.4)         50 (1.7)      0.32           
  Diabetes                      Yes                9 (0.9)          15 (1.6)      0.21          0.34
                                No                 58 (1.9)         63 (2.0)      0.62           
  Stroke                        Yes                13 (2.1)         15 (2.3)      0.75          0.94
                                No                 54 (1.6)         63 (1.9)      0.38           
  Myocardial infarction         Yes                8 (2.7)          7 (2.3)       0.71          0.49
                                No                 59 (1.6)         71 (1.9)      0.25           
  Hypertension                  Yes                48 (1.7)         57 (2.0)      0.40          0.98
                                No                 19 (1.6)         21 (1.8)      0.64           
  Depression                    Yes                8 (2.9)          8 (3.0)       0.83          0.51
                                No                 35 (1.0)         49 (1.5)      0.14           
  Antidepressant medication     Yes                11 (4.0)         13 (4.6)      0.67          0.99
                                No                 56 (1.5)         65 (1.8)      0.37           
  Corticosteroid medication     Yes                10 (3.3)         13 (4.7)      0.05          0.98
                                No                 57 (1.5)         65 (1.7)      0.46           
  Osteoporosis Medication       Yes                4 (1.3)          5 (1.8)       0.37          0.62
                                No                 30 (0.8)         31 (0.8)      0.44           
  Homocysteine                  \< median          10 (3.2)         10 (3.5)      0.77          0.81
  (median 12.6 micromol/L)      (n = 595)                                                       
                                \> = median        8 (2.7)          12 (3.8)      0.53           
  (n = 610)                                                                                     

###### 

Mean homocysteine concentration at follow up\* according to treatment group and fracture outcomes

                             **With fracture mean (standard deviation)**   **Without fracture mean (standard deviation)**   **Difference, (95% confidence interval)**   **P-value (paired t-test)**
  -------------------------- --------------------------------------------- ------------------------------------------------ ------------------------------------------- -----------------------------
  Homocysteine (micromol/L                                                                                                                                               
  Placebo (n = 584)          15.7 (5.9) (n = 23)                           14.2 (6.1) (n = 561)                             −1.52 (−4.08,1.04)                          0.2447
  B-Vitamins (n =580)        11.7 (9.6) (n = 18)                           10.5 (4.6) (n = 562)                             −1.17 (−3.46,1.11)                          0.3118

\* The difference between baseline and follow-up Homocysteine levels were also compared between patients with and without facture. The differences are not significant, either (data not shown).

Note: Only a small subset of patients (14.3%) had homocysteine levels measured at final follow up.

Effect of trial medication on homocysteine, folate and vitamin B12 levels
-------------------------------------------------------------------------

Of the 1164 (14.3%) study participants who volunteered to have optional fasting plasma tHcy levels measured at their final follow-up visit, patients in the B-vitamins group had a mean 3.8 μmol/L (95% CI 3.1-4.4 μmol/L) lower tHcy level compared with placebo (10.5 vs. 14.3 μmol/L, p \< 0.001). Table  [5](#T5){ref-type="table"} compares folate and vitamin B12 levels between baseline and final follow up visits in the small subset that volunteered to provide these.

###### 

Mean homocysteine, red cell folate and vitamin B12 concentration at baseline and follow up according to treatment group

                                  **Baseline: mean (standard deviation)**   **Follow-up: mean (standard deviation)**   **Difference (95% confidence interval)**   **P-value (paired t-test)**
  ------------------------------- ----------------------------------------- ------------------------------------------ ------------------------------------------ -----------------------------
  **Homocysteine** (micromol/L)                                                                                                                                    
  Placebo (n = 463)               13.4 (5.0)                                14.3 (5.7)                                 0.88 (0.40,1.36)                           \<0.001
  B-Vitamins (n = 462)            13.5 (6.3)                                10.5 (4.2)                                 −3.06 (−3.53,-2.59)                        \<0.001
  **Red cell Folate (**nmol/L)                                                                                                                                     
  Placebo (n = 173)               895.0 (466.6)                             1135.2 (666.8)                             244.8 (151.0,338.7)                        \<0.001
  B-Vitamins (n = 183)            959.2 (464.1)                             2181.5 (752.3)                             1220.0 (1117,1341)                         \<0.001
  **B 12** (pmol/L)                                                                                                                                                
  Placebo (n = 190)               317.6 (140.8)                             315.3 (188.9)                              −2.3 (−26.4,31.1)                          0.87
  B-Vitamins (n -- 196)           322.1 (150.8)                             594.7 (271.9)                              272.6 (235.2,310.0)                        \<0.001

Note: Only small subsets of patients had homocysteine, folate and vitamin B12 measured at both baseline and follow up.

Adverse events
--------------

Vitamin B12 deficiency was diagnosed during follow up in none of the 4089 patients in the B vitamins group compared with six (0.1%) of 4075 patients in the placebo group (p = 0.02). Peripheral neuropathy suspected to be caused by vitamin B6 toxicity was diagnosed in five patients assigned to B vitamins (0.1%) compared with nine patients assigned to placebo (0.2%; p = 0.30). There were no unexpected serious and non-serious adverse events and there were no significant differences in common adverse effects between the treatment groups (data not shown).

Discussion
==========

This study did not identify any effect of daily treatment with B-vitamins for a median of 2.8 years on the overall incidence of any clinically apparent osteoporotic fracture or osteoporotic hip fractures during a median of 3.4 years follow-up in 8,164 patients with recent stroke or TIA participating in the VITATOPS study.

The study findings of a lack of effect of B vitamins on osteoporotic fracture are consistent with those of the HOPE-2 trial, in which 5522 patients at risk of vascular disease were treated with B-vitamin therapy for a prolonged period (mean 5 years) and tHcy was lowered by a similar amount (3.8 μmol/L in VITATOPS and 3.3 μmol/L in HOPE-2) compared with placebo \[[@B20],[@B21]\]. Our results in patients with recent stroke or TIA are at odds however with the positive findings of the smaller trial of B-vitamins in disabled Japanese stroke survivors with high tHcy concentrations \[[@B23]\].

The study's strengths include the large number of patients (8164) and their recruitment from a broad range of centres, countries and ethnic groups; the randomization process minimising any systematic bias in treatment allocation; and the blinding of all assessors, clinicians and patients to treatment allocations minimising observer bias.

The most significant limitation of the study was that it was underpowered to reliably identify or exclude a modest but still clinically important effect of B-vitamins on fracture rates as there was only a small number of fracture events resulting in wide 95% confidence intervals for the estimate of relative risk for any fracture with B-vitamin therapy compared with placebo - ranging from up to a 38% reduction to an 18% increase. The low absolute fracture rate most likely reflects the study population with predominance of men (64%), people of non-Western European descent (58%) and younger patients (mean age 62.6 years) who are recognised to have lower rates of fracture \[[@B1],[@B27]\]. Further, most patients with stroke or TIA enrolled in the trial were functionally independent (75%) and therefore not at high risk of falls and fractures \[[@B28]\] unlike those recruited into the positive study of Japanese stroke survivors \[[@B23]\]. In addition, few patients had pre-existing osteoporosis at time of randomisation, as identified by low concurrent use of common osteoporosis preventative and treatment medications (7%). To reliably detect a modest but potentially clinically important 15% relative risk reduction (RRR) with 80% power in this study population who appear to be at relatively low risk of fracture would require a study with over 75,000 participants; more than nine times that recruited to VITATOPS. Even if a statistically significant 14% RRR were proven, an absolute risk reduction of 0.27% (B-vitamins 1.64% and placebo 1.91%) would equate to a number needed to treat of 370 to prevent one fracture in 3.4 years.

Adherence to study medication was also incomplete, although similar between the two treatment groups. This may have biased the results toward the null hypothesis and reflects the difficulties inherent in investigator-led trials conducted with limited peer-reviewed funding \[[@B29]\].

It is possible that the median duration of adherence to treatment (2.8 years) and follow up (3.4 years) in VITATOPS was insufficient to identify or exclude any longer-term effects of therapy with B-vitamins on fracture risk. However, this is longer than most other published studies, with the sole exception of the five-year follow-up in the HOPE-2 trial \[[@B17]-[@B23]\].

An additional limitation was that ascertainment of all fracture outcome events may have been inadequate due to incomplete identification of minor fractures as efforts were focussed on identifying major vascular events, the primary study outcome. The relatively high proportion of all fracture outcomes due to hip fractures (48%) supports this possibility. Fracture ascertainment may also have been incomplete prior to prospective reporting of fractures in 2004; however, exclusion of those patients randomised before 2004 did not alter the findings. The study results were consistent when analysis was restricted to participants with hip fractures, an event that usually results in hospitalisation and is readily identified.

Conclusions
===========

In summary this study did not identify any effect of once daily therapy with folic acid, vitamin B~6~ and vitamin B~12~ for a median of 2.8 years on the overall incidence of osteoporotic fractures during a median of 3.4 years follow-up in 8,164 patients with recent stroke or TIA participating in the VITATOPS study.

A modest effect of B-vitamin therapy is not excluded due to the low numbers of fracture outcome events. Whilst awaiting the results of further prospective randomized controlled studies \[[@B30]\] our data suggests no adverse or favourable effect of homocysteine-lowering with B-vitamins on fracture outcomes.
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